TORONTO – Health Canada has granted a medical license to Toronto-based pharmaceuticals company Hls Therapeutics Inc. for a device that simplifies blood monitoring for patients suffering from treatment-resistant schizophrenia (TRS).
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific.